Health Care·Life Sciences Tools & Services·$8.5B
BIO-TECHNE CORP operates in the health care sector, focusing on life sciences tools and services. The company provides essential products and technologies that support research and development in the life sciences, making it a key player in advancing health care solutions.
Earnings Per Share (EPS)
EPS is a critical measure of profitability and will indicate how well the company is managing costs and generating income.
Revenue Growth
While specific revenue figures are not available, growth in this area is vital for assessing the company's market performance and demand for its products.
Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
8Q
EPS Beat Rate
100%
Avg EPS Surprise
+22.04%
Avg Stock Reaction
+1.96%
In Q2-2026, BIO-TECHNE reported an EPS of $0.46, surpassing expectations by 35.29%. The stock reacted positively, increasing by 6.25% the following day.
Management Promises & Guidance
Investors are cautiously optimistic ahead of the earnings report, given the company's strong track record of beating EPS estimates. However, the lack of specific revenue guidance adds uncertainty.
Bull Case
If BIO-TECHNE continues its trend of exceeding EPS estimates, it could lead to a significant stock price increase, especially if accompanied by positive commentary on future growth.
Bear Case
Conversely, if the company fails to meet expectations or provides weak guidance, it could trigger a sell-off, particularly given the current market volatility.
Earnings Per Share (EPS)
N/AEPS is a critical measure of profitability and will indicate how well the company is managing costs and generating income.
Revenue Growth
N/AWhile specific revenue figures are not available, growth in this area is vital for assessing the company's market performance and demand for its products.
The print will turn on these two things.
Q1
What will the EPS be for Q3-2026?
Given the company's history of beating EPS estimates, this figure will be crucial for determining market sentiment and stock movement.
Q2
How is BIO-TECHNE addressing market demand for its products?
Understanding the company's strategy to meet demand will provide insight into its growth potential and competitive positioning.
Why consensus could be wrong
The Street may be underestimating BIO-TECHNE's ability to leverage new product lines, which could drive unexpected revenue growth this quarter.
Supporting Evidence
The company has consistently beaten EPS estimates, indicating strong management performance.
Options pricing suggests a larger move than historical averages, hinting at potential surprises.
Recent trends in the life sciences sector indicate increased demand for innovative tools and services.
Key Risk
If the company announces a significant new product launch or partnership, it could dramatically shift market expectations.
Pre-commit to what would confirm each case.
The market is weighing the company's ability to maintain its growth trajectory against potential headwinds in the health care sector.
Bull Confirmed If
An EPS of $0.50 or higher would confirm strong operational performance and market demand.
Bear Confirmed If
An EPS below $0.40 could indicate underlying issues in revenue generation or cost management.
Implied Move
±9.73%
Historical Avg
±7.0%
The options market is pricing in a significant move, suggesting that traders anticipate volatility around the earnings announcement.
Options are pricing ±9.7% while TECH has averaged ±7.0% over the last 8 prints — setup is pricing rich.
Likely market behavior by outcome — not investment advice.
Beat & Raise
If BIO-TECHNE beats expectations, history suggests a potential stock increase of around 1.96%, confirming strong operational performance.
In-Line / Cautious
If results are in line with expectations, the stock may see muted movement as investors await further guidance.
Miss
A miss could lead to a decline, with historical patterns suggesting a potential drop of around 1.90%.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
PARAMOUNT SKYDANCE C Class B
May 4, 2026